In a comparison between GLP-1RAs and SGLT2 inhibitors, 105,794 patients were included in the GLP-1RA cohort, and 69,826 patients were in the SGLT2 inhibitor cohort
doi: 10.1016/j.neubiorev.2017.03.007 112 KrishnanV.NestlerE
In combination with healthy lifestyle changes, there is not one that is more effective than the other
Several DPP-4 inhibitors with distinct structures have been approved for clinical use, including sitagliptin, alogliptin, linagliptin, gemigliptin, anagliptin, and teneligliptin (22) (Appendix 1 in Supplementary File)
[7] GLP1R is composed of two domains, one extracellular (ECD) that binds the C-terminal helix of GLP-1, [8] and one transmembrane domain (TMD) [9] that binds the N-terminal region of GLP-1